dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Vastused

Sotsiaalministeerium · 18. mai 2021
Viit
1.1-12/1068
Registreeritud
18. mai 2021
Dokumendi liik
Sissetulev kiri
Adressaat
T. E.
Saabumis/saatmisviis
e-post
Funktsioon
1.1 Juhtimine, arendus ja planeerimine
Sari
1.1-12 Ministeeriumi moodustatud komisjonide ja töögruppide tegevuse korraldamine (Arhiiviväärtuslik)
Toimik
1.1-12
Vastutaja
Ele Riipus

Failid

  • 📎13. Lisaküsimused_DataSHIELD_17.05.21.asice129 KB
  • 📎E-kiri.pdf70 KB

Sisu (failidest)

Saatja: Tõnu Esko <[email protected]> Saadetud: 17.05.2021 23:50 Adressaat: Maria-Helena Rahumets <[email protected]>; SM Info <[email protected]> Koopia: <[email protected]>; Ene Mölder <[email protected]> Teema: Vastused – Re: EBIN otsus väljastatud 06.05.21 Tere Maria-Helena Lisaküsimuste vastused taotlustele 04. ning 07. edastati Ene Möldri poolt täna varem. Käesolevaga lisan digiallkirjastatud ümbriku Lisaküsimuste vastused taotlusele 13. Lugupidades Tõnu Esko On Thu, May 6, 2021 at 5:49 PM Maria-Helena Rahumets <> wrote: Tere! Edastan EBIN-i lisaküsimused Teie taotlustele. Parimate soovidega Maria-Helena Rahumetsnõunik 626 9132 | SotsiaalministeeriumSuur-Ameerika 1 | 10122 Tallinn626 9301 | Eesti bioeetika ja inimuuringute nõukogule esitatud taotlus „ Geenivaramu andmete vastutustundliku jagamise võimaldamine andmekaitse nõuetele vastava koondandmete analüüside kaudu “ vastutava uurija Tõnu Esko poolt. 06. mai 2021 esitatud k üsimused: Palume taotlust täiendada selgitustega, mis on uuringu eesmärk. Praegu ei selgu üheselt, mis on nn praktiline probleem/küsimus, mida uuringu läbiviimise lahendada soovitakse. Antud pilootu uringu eesmärk on katsetada ning edaspidi kasutusele võtta R vabavaralisel programmeerimise keskkonnas arendatud DataSHIELD andmeanalüüsi platvormi, mis võimaldab teostada väga keerukaid epidemioloogilisi uuringuid ning rakendada mitmemõõtmelise statistika meetodeid nii, et uurijad indiviidipõhiselt pseudonüümsetele andmetele ligipääsu ei saa. Kuna lähtuvalt Euroopa Liidu andmekaitse direktiivist (EU GDPR) liigituvad eriliigilisteks isikuandmeteks, kehtivad taoliste andmete analüüsiks kõrgendatud andmekaitse nõuded. Näiteks keeld andmete analüüsiks avalikus pilves ilma krüpteerimata või tähelepanek, et eriliigilisi isikuandmeid ei ole võimalik anonümiseerida . Antud pilootuuringu käigus kaardistatakse kasutajamugavust ning funktsionaalsust, hinnatakse arvutusvõimekust ning -kiirust, ja testitakse arvutuskeskkonna turvalisust ning piiranguid isikutuvastusele. Kui pilootfaas on edukas, on plaanis antud platvorm võtta kasutusele Geenivaramu andmete kättesaadavaks tegemiseks teadustööks. Sektsiooni 10 on lisatud uuringu eesmärk järgnevalt – „ Our main goal is to develop an infrastructure to allow performing non- disclosive data analysis including highly sensitive genomic data and their integration with medical records and questionnaire data . Furthermore , research team will test computational efficiency and speed , will evaluate information security and data privacy measures , and will evaluate user experience and intuitivity of the platform . “ Palume selgitada , miks on vaja infrastruktuuri väljatöötamiseks kasutada kõigi geenid o onorite kõikvõimalikke andmeid ning kas kõigi andmete kasutamine on tarvilik (sealjuures kas esineb siiski teatud fikseeritud andmete koosseis, mida esitada ning mis on põhjendatud)? Antud pilootu uringu raames on vajalik kasutada kogu Geenivaramu valimi (202,000) imputeeritud geneetilisi profiile ning ICD10 põhinevaid diagnoosi koode ja LOINC süsteemis labori näite. Kirjeldatud andmekoosseis on vajalik analüüsi platvormi täiemahuliseks testimiseks, sh erinevate andmetüüpide ning andmemahtude analüüsimise Sektsiooni 1 1 . 3 on lisatud andmekooseisu kirjeldav lõik – „ Phenotype data needed for each participant : * Disease status (ICD10) and clinical lab values ; * Basic demographics ( age , gender , education , smoking, alcohol use , measures of obesity ) “ Sektsiooni 12b.1 on lisatud andmekooseisu kirjeldav lõik – „ Yes , individual genetic profiles and healthcare data ( limited to ICD10 diagnostic codes and LOINC system clinical labs ) will be processed in the course of the research project . All data is pseudomized and only available through password-controlled environment “ . Sektsiooni 1 3 . 3 on lisatud andmekooseisu kirjeldav lõik – „ Research uses data of all 202,300 gene donors available ( limited to imputed genetic profiles , ICD10 diagnostic codes and LOINC system clinical labs ) . Aim of the research is to develop , test and set up an analytical platform for safe environment for privacy-preserving way . “ REQUEST TO THE ESTONIAN COMMITTEE ON BIOETHICS AND HUMAN RESEARCH FOR ETHICAL EVALUATION OF THE STUDY PROPOSAL 1. Name of the study (in case of a request in English, the name of the study in Estonian is required in parallel) Enabling responsible data sharing of Estonian Biobank through privacy-protected federated data analyses Geenivaramu andmete vastutustundliku jagamise võimaldamine andmekaitse nõuetele vastav a koondandmete analüüside kaudu 2. The main purpose of the study (up to 450 letters / 0.25 pages) (in case of a request in English, the name of the study in Estonian is to be given in parallel) The goal of this study is to provide an infrastructure to allow non-disclosive data analyses of sensitive data from Estonian biobank. Our infrastructure will allow the researchers exploring both health records and genomic data in a privacy-protected manner . This will have three main strengths: 1) Data transfer agreement (DTA) is not necessary since data will be stored at local servers of the University of Tartu and will be controlled by the local data custodians (this will fulfil one of the main issues about data sharing policies); 2) Data analyses are performed following ethical-legal regulations surrounding confidentiality and hence, GDPR will be guaranteed; and 3) Research labs will easily be able to carry out state-of-the-art analyses . Selle uuringu eesmärk on pakkuda infrastruktuur i , mis võimaldaks Eesti geenivaramu tundlike andmete turvalist analüüsi. Meie infrastruktuur võimaldab teadlastel uurida nii terviseandmeid kui ka genoomiandmeid viisil, mis tagab isikuandmete salastatuse . Sellel on kolm peamist tugevust: 1) Andmeedastusleping (DTA) ei ole vajalik, kuna andmeid hoitakse Eesti geenivaramu kohalikes serverites ja neid kontrollivad kohalikud andmekogujad (see täidab ühe peamise probleemiga andmete jagamispoliitika osas); 2) andmete analüüs toimub konfidentsiaalsust käsitlevate eetiliste-juriidiliste eeskirjade järgi ja seega tagatakse GDPR nõuete täitmine ; 3) Teaduslaborid, kellel pole kõrg e tasemelisi arvutusoskusi ja / või infrastruktuure, saavad hõlpsasti teha tipptasemel analüüse kasutades Tartu Ülikooli Teadusarvutus keskuse infrastruktuuri ning väljapakutud DataSHIELD platvormi . 3. Principal investigator(s) and the corresponding contact(s) Given name(s): Juan R Last name: Gonzalez Position: Associate Research Professor Institution: Barcelona Institute for Global Health ( ISGlobal ) Phone: +34 93 214 7300 e-mail: [email protected] Given name(s): Tõnu Last name: Esko Position: Professor of Human Genomics Institution: Institute of Genomics, University of Tartu Phone: +372 53408499 e-mail: [email protected] 4. Other researchers involved in the study (add lines as necessary) Given name(s): Demetris Last name: Avraam Position: Research Associate Institution: Population Health Sciences Institute, Newcastle University, UK Given name(s): Paul Last name: Burton Position: Professor of Data Science for Health Institution: Population Health Sciences Institute, Newcastle University, UK Given name(s): Yannick Last name: Marcon Position: Software engineer Institution: EPIGENY Given name(s): Xavier Last name: Escriba Position: PhD Student Institution: Barcelona Institute for Global Health ( ISGlobal ) 5. Financing of the study Sources of funding European Union’s Horizon 2020 research and innovation programme under grant agreement No 874583 (ATHLETE) and No 824989 (EUCAN-Connect) [JRG] . Personal Research Grant (PRG) nr 1291 (2021-2025), Estonian Research Coun ci l [TE]. Total cost of the study (sum) ATHLETE 4M€ / EUCAN-Connect 1,5M€ / PRG1291 1.2M€ Financial compensation for the study participants (yes, no, reasoning and sum) No compensation for participants are foreseen. No new data collected. Insurance provided for the study participants (yes, no, name of the insurer and, if possible, the certificate of insurance (COI)) Not applicable 6. Time period of conducting the study (the beginning and end dates given at month and year level precision) Ma y 2021 – December 202 5, ba sed on the duration of co-PI Dr Esko personal research grant. This will allow to further develop platform functionalities and add other implementations . DataSHIELD framework is aimed to become the standard data processing path for Estonian Biobank collection. 7. Information about previous or consequent evaluation of the same study project ( incl in other countries) This current study has been preceded by several research projects, but the planned research in Estonian Biobank has not been evaluated elsewhere before. The PI has a long collaboration with Prof Tõ nu Esko in exploiting genomic data from University of Tartu since we have gained access to Estonian Biobank in several projects (genomic inversions, loss of chromosome Y and others ) , which have resulted with many innovative an d high impact publications. We have also gained access to multiple surveys and biobanks across Europe and the US, where earlier data applications were approved. These include the UK Biobank and many different datasets from dbGaP . We also have access to some ( EGA ) databases having genomic, transcriptomic and epigenomic data. 8. Brief overview of previous studies on the same subject (up to 900 letters / 0.5 pages) Performing analysis on data from biobanks, requires non-disclosive methods due to ethical-legal restrictions surrounding confidentiality. Different infrastructures have been developed to overcome this issue and allow privacy-preserving data analyses. For example the Canadian Distributed Infrastructure for Genomics platform provides a tool for secure distributed analysis of Canadian-scale genomic and other health data while keeping data private under local control. Another example is DataSHIELD 1 which is an open-source tool that was initially developed under the P3G project in which the Estonian Biobank was an active partner, and was created to address all data sharing and data access related restrictions. First, it allows access to individual data through aggregated information that allows to analyze data using most of the standard statistical methods. Second, it deals with the additional requirements when co-analysing information that may be sensitive from different sources, without physically sharing the data. DataSHIELD has implemented most of the state-of-the-art method to perform the required statistical analyses in different settings including, biomedicine, epidemiology or social science studies in a non-disclosive manner. 2 DataSHIELD is being used by several projects aiming to developed tools for data harmonization, database integration and federated data analyses such as BioSHaRE 3 or EUCAN-connect. 4 It is also used in other projects aiming to integrate data analyses of different cohorts such as LifeCycle 5 or ATHLETE 6 among others. To date DataSHIELD has primarily been applied to research settings (typically large cohort studies) where the emphasis has been on the provision of robust disclosure control for analysing sensitive data. But in big data analyses (such as genomic or clinical records data) the emphasis is more typically on fast, efficient analysis and data generators/custodians and the bodies responsible for data governance often require a relatively basic level of disclosure control. This is the case of Biobanks who would like data to remain with their usual generators/custodians – i.e. a federated approach avoiding the physical transfer of data to users - and for analysts to be unable to see, copy, capture or otherwise infer, those individual-level data. We have recently worked on DataSHIELD capacities for the wider adoption of federated approaches to genomic and big data analysis ( https://isglobal-brge.github.io/resource_bookdown/ ). In this project we aim to implement this infrastructure to allow data sharing of Estonian Biobank data by allowing non-disclosive analyses using state-of-the-art methods. References 1. Wilson, R. C. et al. DataSHIELD – New Directions and Dimensions. Data Sci. J. 16 , (2017). 2. DataSHIELD . Available at: https://github.com/datashield. (Accessed: 26th March 2020) 3. Doiron, D. et al. Data harmonization and federated analysis of population-based studies: The BioSHaRE project. Emerg . Themes Epidemiol . 10 , 12 (2013). 4. EUCAN Connect. Available at: https://www.eucanconnect.eu/. (Accessed: 26th March 2020) 5. Home - LifeCycle . Available at: https://lifecycle-project.eu/. (Accessed: 26th March 2020) 6. Advancing Tools for Human Early Lifecourse Exposome Research and Translation | ATHLETE Project | H2020 | CORDIS | European Commission. Available at: https://cordis.europa.eu/project/id/874583/es. (Accessed: 26th March 2020) 7. Doiron, D. et al. Residential air pollution and associations with wheeze and shortness of breath in adults: A combined analysis of cross-sectional data from two large European cohorts. Environ. Health Perspect . 125 , (2017). 8. Pastorino, S. et al. Associations between maternal physical activity in early and late pregnancy and offspring birth size: remote federated individual level meta‐analysis from eight cohort studies. BJOG An Int. J. Obstet. Gynaecol . 126 , 459–470 (2019) 9. Rationale for the planned study and research questions and / or hypotheses (up to 1800 characters, 1 page) Biobanks containing human biological samples and associated data are key resources for the advancement of medical research. Efficient access to data increases competitiveness in medical research, reduces effort and time for achieving scientific results and promotes scientific progress. Enabling responsible access to biobank data requires innovative solutions improving interoperability in fields such as genetic epidemiology as well as governance including ethical , data privacy and legal frameworks. Rights and expectations of donors to determine the usage of their biological material and data and to ensure their privacy have to be preserved . Our research question is to develop, test and provide a platform for allowing researchers worldwide to analyze Estonian-scale data while keeping data private and under local control. O ur hypothesis is that DataSHIELD is the right infrastructure that permits data analysts from external research organizations to have non-disclosive access to data held by Estonian B iobank. In these circumstances non-disclosive analysis means the data analysts can request analytical operations be performed on the data, but the results of such analysis are summary statistics ( e.g allele frequencies of a given SNP, p-value of association between a given phenotype and SNP, average of BMI for a given group of people, mean age of individuals diagnosed with a given disease and similar) which conform to legal, ethical and governance constraints which are being upheld by the organization. To be clear, at no point will the data analyst have direct access to the data, or a copy of the data. The non-disclosive analysis is achieved by utilizing DataSHIELD , which is essentially a set of R functions collected into R packages. This is an important asset since data analyses are performed under a widely-used environment and, hence, it will facilitate the use of the proposed infrastructure to a broad range of data scientists. The DataSHIELD packages are split into client-side and server-side packages. The DataSHIELD client-side packages are used by the data analysts and the DataSHIELD server-site packages are deployed within the organization’s Opal server (i.e. University of Tartu, High Performance Computing Center ), through which analytical operations can be performed. The figure in the next page illustrates the reference deployment of DataSHIELD including Opal and describes how a risk assessment process is undertaken. The purpose of the components and interactions within the reference deployment are: Data Analyst: the node from which data analysts make analysis request to the Server, and receive analysis results; External Firewall: the firewall between the data analysis and Server; Internal Firewall: the firewall between primary and secondary data service; Analysis Requests: the request sent by the data analysis to DataSHIELD , via the Server; Analysis Results: the non-disclosive results send from DataSHIELD to the data analysis,via the Server; Server (Opal): the Server manages: authentication and authorization of sessions and demultiplexing of requests to the R Parser or Web Portal. User authentication, but the Server, can be performed via password or certificate (hosted at UT High Performnce Comuting Center ) ; Web Portal: within the Server provides a web based administrative interface to Opal server; Admin API: within the Server provides a REST based administrative interface to Server; R Parser: the R parser checks the analysis requests only contain valid requests, and in particular only permitted non-disclosive functions; Primary Data Service: this data service contains the primary copy of the data to be analysed; Secondary Data Service: the data service, which could be provided by MySQL or mongodb , contains the secondary copy of the data to be analysed. This version of the data will be copied into the R server to be analysed; R Server: the R server is an execution environment, one per user, within which analysis requests are executed; DataSHIELD : an R package, within the R server, which provides data analytic functions. For clarity – all research teams have to obtain relevant approvals and ethics asses s ments from the Estonian Bioethics and Human Research Committee . Also, all Estonian Biobank data will be hosted at the University of Tartu High Performance Computing Centre behind a strict firewall and researchers must obtain authorization from University of Tartu in order to access the data. All processes and analytical steps will be audition-grade logged and systematically stored. 10. Research methodology (up to 1800 characters, 1 page) Our main goal is to develop an infrastructure to allow performing non-disclosive data analysis including highly sensitive genomic data and their integration with medical records and questionnaire data. Furthermore, research team will test computational efficiency and speed, will evaluate information security and data privacy measures, and will evaluate user experience and intuitivity of the platform. Next we describe the key aspects of our research methodology : Architecture Our infrastructure will be built to be completely distributed. To this end, DataSHIELD and Opal data warehouse will be used. In terms of computation facilities, the project will require a general Opal server in which the R based analyses will be conducted. As some data analyses can be highly computational demanding ( e.g. genome analyses) some of them will be delegated to High Performace Computing service (HPC) . Both Opal server and HPC infrastructure will be hosted at University of Tartu facilities. Existing DataSHIELD R packages will be used to allow non-disclosive data analyses using state-of-the-art methods in biomedical studies. Some new methods will be implemented to allow advanced genetic epidemiology studies. These will be incorporated in our DataSHIELD package which is already available to analyze omic data ( https://rpubs.com/jrgonzalezISGlobal/tutorial_DSomics ) . Data security Institute of Genomics will handle Estonian Biobank data and users, with complete control over who can access (in a privacy-protected manner) each data set and how much, with federated analysis built on top of APIs to this data. As a result, Estonian Biobank’s data will be analyzed without being copied. For authentication, we are using best-practices for RESTful API authentication, such as OpenID Connect. All researchers must obtain an ethics approval from EBIN. A disclosure preventing infrastructure The infrastructure will include disclosure controls available in DataSHIELD : a) build on robust hardware and encrypts all transmissions; b) build upon formal governance agreements; c) the server-side R is only callable via a middleware (Opal, https://www.obiba.org/pages/products/opal/ ) that takes care of the authentication and authorizations; d) this middleware also includes an R parser that permits only valid functions, arguments and characters to pass from client-side to server-side; e) the data stored on the servers are pseudonymised (direct identifiers are suppressed); f) the server-side functions do not output any disclosive information; g) existence of a number of disclosure traps (e.g. for allowed min cell size, for glm saturation, etc); h) the data custodian controls the traps’ thresholds; i ) the system logs all commands/outputs on remote servers; j) is attached to a bespoke database behind each study’s firewalls. Implementing new privacy-preserving statistical methods for genomic data analysis We will implement new functions to perform data analysis from IMPUTED data which is already available at the Institute of Genomics for Estonian Biobank cohort . To this end, a new resource infrastructure will be created to deal with the SNPTEST program. New statistical methods will also be implemented to carry out advanced data analyses including polygenic risk scores and multivariate data analyses. These new functions will be incorporated into our R package dsOmics ( https://rpubs.com/jrgonzalezISGlobal/omicsDataSHIELD ) that already has functions to perform basic genomic data analyses in DataSHIELD such as quality control for individuals and SNPs, population stratification, allele frequency estimates and genetic association tests using Bioconductor and PLINK ( https://isglobal-brge.github.io/resource_bookdown ). Scalability Our new infrastructure will also interface with Big Data storage and analytics systems, such as "Apache Spark" or " Dremio ", that will facilitate to carry out the standard statistical methods required in big data analyses ( e.g. medical records and/or genomics) by implementing efficient and scalable methods. Our infrastructure will interact with Apache Spark using SparkR and Dremio through our package odbc.resourcer ( https://github.com/obiba/odbc.resourcer ). 11. Sample of subjects and description of recruitment method. Information and consent forms, questionnaires and tests should be submitted as annexes to the application. Sample size and presence of control groups Data of all Estonian Biobank participants (gene donors) available in the Estonian Biobank having genomic data – currently 202 300 samples . Who recruits and how / where / through whom is informed consent obtained? (if applicable) We are going to use only already existing data. No new gene donors will be recruited, or new data collected. How and from whom are the subjects selected? What are the criteria for inclusion or exclusion of subjects? All gene donors who have genotype data , medical records (disease) and other data types available at the Biobank Phenotype data needed for each participant: Disease status (ICD10) and clinical lab values Basic demographics (age, gender, education, smoking, alcohol use, measures of obesity) Type of interventions (physical, mental or data, including special category personal data) Research use health and genomic data in pseudonymised form Burden on the subject (methods of contact, number of visits, type and number of studies, repetition of invitations, etc.) No burden to the participants 12. Analysis of the ethical aspects of the study (3600 characters, up to 2 pages). All research involving humans must be carried out in compliance with ethical requirements, in particular the principles of respect for autonomy, charity and the prevention of harm, and justice. ( https://www.coe.int/en/web/bi oethics/guide-for-research-ethics-committees-members ). Please see https://ec.europa.eu/research/participants/data/ref/ h2020/grants_manual/hi/ethics/h2020_hi_ethics-self-assess_en.pdf The project is carried out on the basis of the Human Genes Research Act (HGRA) and other legislation concerning the work of the EBB. The principles of bioethics have been taken into account when planning activities. 1. The principle of respect for individual autonomy The main features of the first principle are the voluntary nature of participation in the trial, the existence of written consent and the protection of privacy and personal data. This study will include data from volunteer gene donors of Estonian Biobank . Gene donors have signed a consent form for joining the Estonian Biobank , allowing to use their data for different research purposes. HGRA § 12. Consent to becoming a gene donor. The consent allows to take a tissue sample, describe his or her state of health and pedigree, to encode the genome and to use the information for genetic research, public health research and statistical purposes. Scientists use only pseudonymised data and no data re-encoding by foreign partners will be permitted. Therefore, the threat to the gene donors’ privacy is low. 2. The principle of not doing harm The present study has a research design developed by competent scientists and has the latest technology for performing analyzes . Implementing high-level technology ensures the accuracy and high quality of the research. There is no threat to the data of individuals, as it is not used outside the protocol, and biological material is not used. This study does not cause psychological stress to gene donors. 3. The principle of charity Since in this study gene donors are not contacted initially no direct benefit can be obtained. However, social charity is manifested through scientific innovation and the improvement of the health system. In the long term, the application of research results will be towards more personalized treatment and prevention and diagnosis. 4. The principle of justice This research creates a prerequisite for more effective, safer and better access to health care in society. Estonian Biobank is a population-based biobank, where different social and age groups are represented, the distribution of gender and other demographic features in the Estonian Biobank quite well reflect the composition of the entire Estonian population. Thus, in the long run, all members of society benefit from research. 12 a Subjects (human beings) Assistance questions No Yes Are people the object of research? Yes, given research project will be using Estonian Biobank participant data . Are the target persons vulnerable individuals or groups? X Not applicable Are the subjects of the research persons who cannot themselves give informed consent to participate in the research (incl. persons with limited active legal capacity)? X Not applicable Are the objects of research children/minors? X Not applicable Are the objects of research patients? All research ob j ects are Estonian Biobank participants and consented accordingly. At the moment of inclusion to the projects they are not patients. Does the research involve collection of biological samples? Are human biological samples intended for export to a third country or import them from another country to Estonia? X Not applicable 12 b Personal data No Yes Is personal data collected or analyzed in the course of the research, including special categories of personal data? Yes, individual genetic profiles and healthcare data ( limited to ICD10 diagnostic codes and LOINC system clinical labs ) will be processed in the course of the research project. All data is pseudomized and only available through password-controlled environment. Whether the research involves the systematic monitoring of an individual, the collection of his or her data profile, or the large-scale processing of data of special categories and / or sensitive data, or the use of (intrusive) data processing techniques in a covert way or any data processing that may prejudice the rights and freedoms of the data subject? Research involves processing of personal data – genetic profiles and healthcare data. All participants have provided an informed consent. Does the research analyze previously collected personal data? Yes, all data is provided directly by biobank participants or extracted from national databases according to the Human Genes Research Act (HGRA) Does the research analyze publicly available data? X Whether it is intended to transfer personal data or provide access to them from third countries ? X Will personal data be destroyed / anonymised at the end of the research? Only existing pseudomized data hosted at Estonian Biobank will be used to carry out research aims. No further data will be collected. 12 c Other ethical issues Can conducting research involve ethical risks not described above? X 13. Complete if the research is based on data from a database and / or data source. Name of database and / or data source Estonian Biobank Purpose of the processing of personal data Fulfilling of the aims of the research Data composition and period for which data are collected (as an annex if necessary) Research uses data of all 202,300 gene donors available (limited to imputed genetic profiles, ICD10 diagnostic codes and LOINC system clinical labs) . Aim of the research is to develop, test and set up an analytical platform for safe environment for privacy-preserving way. 14. Description of personal data protection measures, including data retention, storage, security and erasure, including date of erasure of data and / or code key (up to 1800 characters, 1 page). Describe and justify the storage and timing of data collected for the study. All data has already been collected by Estonian Biobank personnel according to the HGRA and participant informed consent Describe the process and means of pseudonymisation of personal data. All personal data in the Estonian Biobank is already pseudonymised. Whether personal data is being transported and describe how data security is ensured. Data will be custodied by University of Tartu and Estonian Biobank. It will not be transported Describe how the data is protected against unauthorized or unlawful processing. Only summary data will be accessed. Individual data is password/token protected by two firewalls (see figure in the section 9) I confirm that all researchers are aware of the ethical and personal data protection requirements of the project. Signature of the principal investigator Date of application 23.03.2021 EBIN ID of the application (fills by the assessor) CV of Tõnu Esko : https://www.etis.ee/CV/T%C3%B5nu_Esko/est List of additional documents: CV of the principal investigator – Juan R Gonzalez
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel